In 2008, a box of 30 anti-inflammatory rectal suppositories that treats arthritis, called Indocin, had a price tag of $198. As of Oct. 1, the price of that same box was 52 times higher, totaling $10,350.
Following a five-month search for a full-time chief executive, Adverum Biotechnologies $ADVM has decided interim CEO Leone Patterson is the best candidate for the job after all. Patterson, who first joined Adverum in 2016, is now responsible for scaling its nascent clinical operation. The gene therapy company will now search for a CFO instead to take over Patterson’s old responsibilities.
Amirall's US dermatology company Aqua Pharmaceuticals has appointed Ron Menezes as its new president and general manager.
Opioid makers have had no shortage of critics in recent years as the United States suffers the sting of a painful addiction epidemic. Now, a top senate Democrat is throwing the weight of her office behind efforts to dig into the industry’s marketing practices for the risky painkillers.
Endo’s ($ENDP) CEO exodus is continuing. Its CFO is following its CEO out the door--to work for another drugmaker, no less.nnThursday, the Dublin company announced that financial chief, Suketu Upadhyay, would be hitting the road to “assume a senior-level finance position at a global biopharmaceutical company.” Blaise Coleman, Endo's SVP of Global Finance Operations, will step up in his stead while Endo searches for a permanent replacement.
Beating the street to market painkillers in Chicago? You might need a license for that soon.nCity officials are proposing a special license for pharma reps who promote powerful pain meds, a measure that Mayor Rahm Emmanuel touts as a weapon against opioid addiction, the Chicago Tribune reports.
Depomed strikes unexpected deal with activist Starboard, adding J&J, Abbott
Depomed has insisted it would be unfair for activist investor Starboard Value to force a special meeting over future control of the company until patent litigation for its key drug, the pain med Nucynta, was resolved. Well, that time is here: A court has ruled in favor of Depomed on its patents.
Depomed’s ($DEPO) okay with a special meeting at which a rebel shareholder hopes to wipe its board clean. It just doesn’t want to do it for another four months.